Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
Ampronix
Schiller

Insertable Monitors Superior in Detecting Cardiac Arrhythmia

By HospiMedica International staff writers
Posted on 08 Jul 2014
Medtronic\'s Reveal XT ICM
Medtronic\'s arrhythmia monitoring solution (Photo courtesy of Physio-Control)
A new study concludes that insertable cardiac monitors (ICMs) detect atrial fibrillation (AF) in stroke patients better than standard care.

Researchers at Campus Bio-Medico University (Rome, Italy), Klinikum Coburg (Coburg, Germany), and other institutions conducted a randomized, controlled study of 441 patients (40 years of age or older) to assess whether long-term monitoring with an ICM is more effective than conventional follow-up (control) for detecting AF in patients with cryptogenic stroke. Patients with no evidence of AF during at least 24 hours of electrocardiogram (ECG) monitoring underwent randomization within 90 days after the index event. The primary end point was the time to first detection of AF within six months.

The results showed that by six months, AF had been detected in 8.9% of patients in the ICM group, versus just 1.4% of patients in the control group, representing a 6.4 times benefit. In addition, the researchers found that compared to standard care—including ECGs, Holter monitors, and other short-term diagnostic tests—the ICM detected AF in 7.3 times more patients at 12 months, and 8.8 times more at 36 months. When followed for 36 months, 30% of the patients in the ICM arm had AF detected. The study was published on June 26, 2014, in the New England Journal of Medicine (NEJM).

“If we can pinpoint the cause of stroke, we then can apply the most appropriate treatment. As AF is often intermittent and asymptomatic, we can't rely on symptoms to decide who has AF or who needs ECG monitoring,” said study coauthor Prof. Johannes Brachmann, MD, chief of cardiology at Klinikum Coburg. “Continuous monitoring of the heart rhythm can help us find those stroke patients whose AF is often missed with short-term monitoring. This can be explained by the amount of time that passes between episodes.”

For the study, the researchers used the Medtronic (Minneapolis, MN, USA) Reveal XT ICM, a comprehensive arrhythmia monitoring solution that automatically classifies rhythm types (atrial tachyarrhythmia/atrial fibrillation (AT/AF), ventricular tachyarrhythmia (VT), bradyarrhythmias, and more). The device helps monitors AT/AF burden to assess whether medical treatment is necessary or should be adjusted, as well as monitoring VT rhythm during atrial arrhythmias to assess the efficacy of rate control therapy.

The Reveal XT ICM has recently been superseded by the Reveal LINQ ICM system, which is approximately one-third the size of a standard AAA battery, and is placed just beneath the skin through a small incision of less than 1 cm in the upper left side of the chest.

Related Links:
Campus Bio-Medico University
Klinikum Coburg
HospiMedica Miniature Implantable Device Monitor article



Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
Free digital version edition of HospiMedica International sent by email on regular basis
Free print version of HospiMedica International magazine
(available only outside USA and Canada).
Free and unlimited access to back issues of HospiMedica International in digital format
Free HospiMedica International Newsletter sent every 2 weeks containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!


Click here to Register

Sign in: Registered website members
Username: Password:
Forgot username/password? Click here!
Sign in: Registered magazine subscribers
Subcode: Last Name:
What is SUBCODE?


Centurion Service
MinXray
Bovie Medical

Channels

Surgical Techniques

view channel

Living Donor Liver Transplantation Relatively Safe

A new study shows that right liver lobe donor hepatectomy can be performed with minimal complication rates, increasing the potential donor pool dramatically. Researchers at Afyon Kocatepe University (AKU; Afyon, Turkey), Ege University (Izmir, Turkey), and International Kent Hospital (Izmir, Turkey) conducted a study... Read more

Women's Health

view channel
Image: A prototype contraceptive implant (Photo courtesy of MicroCHIPS).

Contraceptive Implant Hails New Era of Birth Control

A fingernail-sized implant holds enough 30-microgram daily doses of levonorgestrel to provide contraception for 16 years. Developed by MicroCHIPS (Lexington, MA, USA), a MIT (Cambridge, MA, USA) startup,... Read more

Business

view channel

Abbott Selling Developed Market Generics Portfolio

Abbott Laboratories (Abbot Park, IL, USA) has sold its developed market generic drugs business to Mylan (Canonsburg, PA, USA) in a deal worth USD 5.3 billion. The sale to Mylan will be in the form of an equity ownership of a newly formed entity, to be named Mylan NV, in which Abbott will have a stake of 21%.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.